Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Teva Pharmaceutical Industries Ltd
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
October 08, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
October 01, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
September 30, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
September 23, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Present at the Bank of America 2024 Global Healthcare Conference
September 11, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
July 31, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.